Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  McCoy, Margaret E ^a   Golden, Hannah E ^a   Doll, Tais A P F ^b   Yang, Yongkun ^b   Kaba, Stephen A ^a   Burkhard, Peter ^b   Lanar, David E ^a  

^a WRAIR   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Circumsporozoite protein; Complement lysis; Dendritic cells; Erythrocytic stage; Plasmodium; Self assembling protein nanoparticle; TAP; Vaccine

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; GOLD NANOPARTICLE; IMMUNOGLOBULIN G1 ANTIBODY; SELF ASSEMBLING PROTEIN NANOPARTICLE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIGEN PRESENTATION; ARTICLE; DENDRITIC CELL; ENDOSOME; FEMALE; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE RESPONSE; LIVER CELL; MALARIA FALCIPARUM; MOUSE; NONHUMAN; PHASE CONTRAST MICROSCOPY; SPOROZOITE; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HEPATOCYTES; MALARIA VACCINES; MICE; MICE, INBRED C57BL; NANOPARTICLES; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84876706457     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-136     Document Type: Article

References (30)

1. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Epstein JE, Tewari K, Lyke KE, Sim BKL, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Richie TL, Seder RA, Hoffman SL, Science 2011 334 475 480 10.1126/science.1211548 21903775
2. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Chattopadhyay R, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe CV, Sim BKL, Hum Vaccin 2010 6 97 106 10.4161/hv.6.1.10396 19946222
3. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. Luke TC, Hoffman SL, J Exp Biol 2003 206 3803 3808 10.1242/jeb.00644 14506215 (Pubitemid 37365462)
4. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia M, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J, Lancet 2004 364 1411 1420 10.1016/S0140-6736(04)17223-1 15488216 (Pubitemid 39370716)
5. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo B, Doucka Y, Flamen A, Mordmuller B, Doucka Y, Flamen A, Mordmueller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Clinical Trials Partnership, et al. N Engl J Med 2011 365 1863 1875 22007715
6. Immunity to malaria: more questions than answers. Langhorne J, Ndungu FM, Sponaas AM, Marsh K, Nat Immunol 2008 9 725 732 18563083 (Pubitemid 351859155)
7. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Pimentel TAPF, Yan Z, Jeffers SA, Holmes KV, Hodges RS, Burkhard P, Chem Biol Drug Des 2009 73 53 61 10.1111/j.1747-0285.2008.00746.x 19152635
8. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Raman S, Machaidze G, Lustig A, Aebi U, Burkhard P, Nanomedicine 2006 2 95 102 10.1016/j.nano.2006.04.007 17292121 (Pubitemid 43956613)
9. Conformation-specific display of 4E10 and 2 F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. Wahome N, Pfeiffer T, Ambiel I, Yang Y, Keppler OT, Bosch V, Burkhard P, Chem Biol Drug Des 2012 80 349 357 10.1111/j.1747-0285.2012.01423.x 22650354
10. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. Kaba SA, Brando C, Guo Q, Mittelholzer C, Raman S, Tropel D, Aebi U, Burkhard P, Lanar DE, J Immunol 2009 183 7268 7277 10.4049/jimmunol.0901957 19915055
11. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a protein nanoparticle vaccine. Kaba SA, McCoy ME, Doll TAPF, Brando C, Guo Q, Dasgupta D, Yang Y, Mittelholzer C, Spaccapelo R, Crisanti A, Burkhard P, Lanar DE, PLoS One 2012 7 48304 10.1371/journal.pone.0048304 23144750
12. Innate immunity to malaria. Stevenson MM, Riley EM, Nat Rev Immunol 2004 4 169 180 10.1038/nri1311 15039754 (Pubitemid 38339083)
13. Induction of the CD23/nitric oxide pathway in endothelial cells downregulates ICAM-1 expression and decreases cytoadherence of Plasmodium falciparum-infected erythrocytes. Pino P, Vouldoukis I, Dugas N, Conti M, Nitcheu J, Traore B, Danis M, Dugas B, Mazier D, Cell Microbiol 2004 6 839 848 10.1111/j.1462-5822.2004.00406.x 15272865 (Pubitemid 39162626)
14. Sterile protection of monkeys against malaria after administration of interleukin-12. Hoffman SL, Crutcher JM, Puri SK, Ansari AA, Villinger F, Franke ED, Singh PP, Finkelman F, Gately ML, Dutta GP, Sedegah M, Nat Med 1997 3 80 83 10.1038/nm0197-80 8986746 (Pubitemid 27019146)
15. Histamine H(3) receptor-mediated signaling protects mice from cerebral malaria. Beghdadi W, Porcherie A, Schneider BS, Morisset S, Dubayle D, Peronet R, Dy M, Louis J, Arrang JM, Mecheri S, PLoS One 2009 4 6004 10.1371/journal.pone.0006004 19547708
16. Essential role of extrathymic T cells in protection against malaria. Mannoor MK, Halder RC, Morshed SRM, Ariyasinghe A, Bakir HY, Kawamura H, Watanabe H, Sekikawa H, Abo T, J Immunol 2002 169 301 306 12077258 (Pubitemid 34686149)
17. Encapsulation of gold nanoparticles into self-assembling protein nanoparticles. Yang Y, Burkhard P, J Nanobiotech 2012 10 10.1186/1477-3155-10-42
18. Functional immunoassays using an in-vitro malaria liver-stage infection model: where do we go from here? House BL, Hollingdale MR, Sacci JB Jr, Richiel TL, Trends Parasitol 2009 25 525 533 10.1016/j.pt.2009.08.004 19747878
19. Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity. Tewari R, Spaccapelo R, Bistoni F, Holder AA, Crisanti A, J Biol Chem 2002 277 47613 47618 10.1074/jbc.M208453200 12244064 (Pubitemid 36159282)
20. Biological role of different antibody classes. Spiegelberg HL, Int Arch Allergy Applied Immunol 1989 90 22 27 10.1159/000235071 (Pubitemid 20043891)
21. CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. Curtsinger JM, Johnson CM, Mescher MF, J Immunol 2003 171 5165 5171 14607916 (Pubitemid 37432800)
22. Unexpected prolonged presentation of influenza antigens promotes CD4 T cell memory generation. Jelley-Gibbs DM, Brown DM, Dibble JP, Haynes L, Eaton SM, Swain SL, J Exp Med 2005 202 697 706 10.1084/jem.20050227 16147980 (Pubitemid 41248420)
23. Development of a sporozoite malaria vaccine. Nussenzweig V, Nussenzweig RS, Am J Trop Med Hyg 1986 35 678 688 2425647 (Pubitemid 16072226)
24. Malaria sporozoites leave behind trails of circumsporozoite protein during gliding motility. Stewart MJ, Vanderberg JP, J Protozool 1988 35 389 393 3054075
25. Further studies on Plasmodium berghei-Anopheles stephensi-rodent system of mammalian malaria. Vanderberg JP, Nussenzweig RS, Most H, J Parasitol 1968 54 1009 1014 10.2307/3277136 4919047
26. Stage specificity of anti-sporozoite antibodies in rodent malaria and its relationship to protective immunity. Vanderberg J, Nussenzweig R, Sanabria Y, Nawrot R, Most H, Proc Helminth Soc Washington 1972 39 514 525
27. Inhibition of development of exerythrocytic froms of malaria parasites by gamm-interferon. Ferreira A, Schofield L, Enea V, Schellekens H, Vandermeide P, Collins WE, Nussenzweig RS, Nussenzweig V, Science 1986 232 881 884 10.1126/science.3085218 3085218 (Pubitemid 16117400)
28. The basolateral domain of the hepatocyte plasma-membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cerami C, Frevert U, Sinnis P, Takacs B, Clavijo P, Santos MJ, Nussenzweig V, Cell 1992 70 1021 1033 10.1016/0092-8674(92)90251-7 1326407
29. Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Singh AP, Buscaglia CA, Wang Q, Levay A, Nussenzweig DR, Walker JR, Winzeler EA, Fujii H, Fontoura BMA, Nussenzweig V, Cell 2007 131 492 504 10.1016/j.cell.2007.09.013 17981117 (Pubitemid 350007696)
30. Specific inhibition of the classical complement pathway by C1q-binding peptides. Roos A, Nauta AJ, Broers D, Faber-Krol MC, Trouw LA, Drijfhout JW, Daha MR, J Immunol 2001 167 7052 7059 11739526 (Pubitemid 33144201)